Treatment with the biologic, benralizumab, was associated with significant reductions in the use of corticosteroids in patients with eosinophilic asthma. The patients participating in the multicenter, open-label PONENTE trial of the biologic drug showed that the patients could discontinue their steroid dependence. Benralizumab’s PONENTE trial, conducted by Menzie-Gow and colleagues to find the efficacy of the biologic drug in steroid-dependent patients with eosinophilic asthma, showed that 63 percent of the patients treated with the IL-5 receptor α-directed monoclonal antibody were able to stop or reduce oral corticosteroid use following a period of personalised tapering based on a steroid-reduction algorithm. They also added that about 82 percent either eliminated usage or achieved a corticosteroid dosage of 5 mg or less when adrenal insufficiency prevented further dose reductions.